Abstract
Drug discovery is a complex process that includes the identification of biological targets as well as the identification of leads that aim at altering or inhibiting the function of a particular target. The budding yeast Saccharomyces cerevisiae has long been recognized as a valuable model organism for studies of eukaryotic cells since many of the basic cellular processes between yeast and humans are highly conserved. In this review, we highlight emerging yeast-based functional genomic and proteomic technologies that are advancing the utility of yeast as a model organism in the drug-discovery process. These approaches include the utilization of yeast deletion strain collection, synthetic genetic array combined with chemical genomics, variations of the yeast two-hybrid system, yeast biosensor assay, and protein microarrays. Although still at an early stage, these technologies show promise as novel and useful methods for development of target-specific therapeutic approaches.
Keywords: drug discovery, yeast two hybrid system, genomics, proteomics
Current Proteomics
Title: Drug Discovery Using Yeast as a Model System: A Functional Genomic and Proteomic View
Volume: 2 Issue: 1
Author(s): Daniel Auerbach, Anthony Arnoldo, Boris Bogdan, Michael Fetchko and Igor Stagljar
Affiliation:
Keywords: drug discovery, yeast two hybrid system, genomics, proteomics
Abstract: Drug discovery is a complex process that includes the identification of biological targets as well as the identification of leads that aim at altering or inhibiting the function of a particular target. The budding yeast Saccharomyces cerevisiae has long been recognized as a valuable model organism for studies of eukaryotic cells since many of the basic cellular processes between yeast and humans are highly conserved. In this review, we highlight emerging yeast-based functional genomic and proteomic technologies that are advancing the utility of yeast as a model organism in the drug-discovery process. These approaches include the utilization of yeast deletion strain collection, synthetic genetic array combined with chemical genomics, variations of the yeast two-hybrid system, yeast biosensor assay, and protein microarrays. Although still at an early stage, these technologies show promise as novel and useful methods for development of target-specific therapeutic approaches.
Export Options
About this article
Cite this article as:
Auerbach Daniel, Arnoldo Anthony, Bogdan Boris, Fetchko Michael and Stagljar Igor, Drug Discovery Using Yeast as a Model System: A Functional Genomic and Proteomic View, Current Proteomics 2005; 2 (1) . https://dx.doi.org/10.2174/1570164053507790
DOI https://dx.doi.org/10.2174/1570164053507790 |
Print ISSN 1570-1646 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6247 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Potentials of Hydrogels in Cancer Therapy
Current Cancer Therapy Reviews Viral Carcinogenesis of Oral Region and Recent Trends in Treatment
Recent Patents on Biomarkers New Development and Application of Ultrasound Targeted Microbubble Destruction in Gene Therapy and Drug Delivery
Current Gene Therapy Retraction Note: Low Doses of CPS49 and Flavopiridol Combination as Potential Treatment for Advanced Prostate Cancer
Current Pharmaceutical Biotechnology Antiviral Medication in Sexually Transmitted Diseases. Part I: HSV, HPV
Mini-Reviews in Medicinal Chemistry The Role of Apoptosis in Cancer Development and Treatment: Focusing on the Development and Treatment of Hematologic Malignancies
Current Pharmaceutical Design Structure and Function of the Epstein-Barr Virus Transcription Factor, EBNA 3C
Current Protein & Peptide Science Pharmacology of TRP Channels in the Vasculature
Current Vascular Pharmacology Is Type 2 Diabetes Mellitus a Predisposal Cause for Developing Hepatocellular Carcinoma?
Current Diabetes Reviews Oncogenic Signalling Networks and Polypharmacology as Paradigms to Cope with Cancer Heterogeneity
Current Proteomics Linking Inflammation to Cell Cycle Progression
Current Pharmaceutical Design The MCM Complex: Its Role in DNA Replication and Implications for Cancer Therapy
Current Cancer Drug Targets Synthetic Methods of Quinoline Derivatives as Potent Anticancer Agents
Mini-Reviews in Medicinal Chemistry The Potential for Substance P Antagonists as Anti-Cancer Agents in Brain Tumours
Recent Patents on CNS Drug Discovery (Discontinued) Cdk5 in the Adult Non-Demented Brain
Current Drug Targets - CNS & Neurological Disorders Voltage Gated Calcium Channels as Targets for Analgesics
Current Topics in Medicinal Chemistry The MYCN Oncogene as a Specific and Selective Drug Target for Peripheral and Central Nervous System Tumors
Current Cancer Drug Targets Prostaglandin J2 Family and the Cardiovascular System
Current Vascular Pharmacology Anticancer Effects of Ginsenoside Rh2: A Systematic Review
Current Molecular Pharmacology Anticancer Drug Design Using Scaffolds of β-Lactams, Sulfonamides, Quinoline, Quinoxaline and Natural Products. Drugs Advances in Clinical Trials
Current Medicinal Chemistry